( gen to preventclot formation and reduc...)Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod),Health

gen to prevent clot formation and reduces blood viscosity, which may lead to improved blood flow within the affected area. Ancrod also indirectly causes the clot to break up. In contrast, other approved drugs or drugs in clinical development for AIS do not directly target fibrinogen. Ancrod has multiple mechanisms of action to help rapidly achieve three biological effects: blood viscosity reduction, thrombus modification, and alteration of hemostasis. The three effects of ancrod provide a potent yet potentially safe means of limiting brain damage with stroke.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. (NTI) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. The Company is focused on therapies for neurological conditions that occur in connection with ischemic stroke, brain cancer, Alzheimer's disease and dementia. The Company's strategy is to in- license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. For further information, please visit NTI's website at http://www.ntii.com.

A full press kit is available at the NTI booth (#171) or by emailing: Kamala@corinthgroup.com

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our need for additional capital, risks related to clinical trials and the regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical developme
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
9. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
10. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
11. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting